The AP3S2 Knockout A-549 Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This mixed-allele pool carries targeted disruption of AP3S2, eliminating the sigma3B subunit of the adaptor protein complex 3 (AP-3). The polyclonal format provides a practical and robust loss-of-function model, avoiding the selection bias associated with monoclonal derivation.
The A-549 host cell line was originally established from lung carcinoma tissue of a 58-year-old male and is a classic model of type II alveolar epithelial cells. It is extensively utilized in lung cancer research and drug metabolism studies, offering a relevant epithelial context for dissecting oncogenic pathways and therapeutic responses.
AP3S2 encodes the sigma3B subunit of the heterotetrameric AP-3 complex, which sorts cargo from the trans-Golgi network to late endosomes and lysosome-related organelles. The complex, comprising ??3 (AP3B1/B2), ?? (AP3D1), ??3 (AP3M1/M2), and ??3 subunits, interacts with clathrin and is regulated by ARF1, phosphatidylinositol 4-phosphate, and LRRK2 kinase. AP-3 directs proteins such as LAMP1, LAMP2, tyrosinase, and VAMP7 to their destinations. Disruption of AP3S2 abolishes sigma3B, compromising complex integrity and impairing lysosomal trafficking, which leads to defective degradation, autophagic flux blockage, and disrupted cellular homeostasis.
In A-549 lung adenocarcinoma cells, AP3S2 knockout allows the exploration of endolysosomal trafficking in a non-neuronal tumor context. Emerging evidence implicates AP-3 function in cancer cell metabolism, growth factor receptor turnover, and chemoresistance. Loss of AP3S2 likely perturbs lysosomal activity and autophagy, potentially altering cell proliferation, migration, and sensitivity to anticancer drugs, thus providing a novel model to study tumor cell biology beyond traditional neuronal roles.
Applications include western blotting and RT-qPCR for AP-3 subunit and cargo expression analysis, immunofluorescence and LysoTracker staining for lysosomal markers, autophagy flux assays, co-immunoprecipitation to probe complex formation, cell viability and drug sensitivity profiling, and wound-healing/invasion assays. This polyclonal knockout pool also supports high-throughput screening for compounds that modulate lysosomal function or rescue trafficking defects. For further information, please contact Ascent Research.
